Optimized radiation of pelvic volumes in the clinical setting by using a novel bellyboard with integrated gonadal shielding
- PMID: 15324913
- DOI: 10.1016/j.meddos.2004.04.004
Optimized radiation of pelvic volumes in the clinical setting by using a novel bellyboard with integrated gonadal shielding
Abstract
The purpose of this study was to determine the feasibility of a custom-made, modified bellyboard to reduce radiotherapy side effects on small bowel, bladder, skin, and male gonads. Two groups of 10 consecutive patients each were treated from January 2003 through April 2003 with neoadjuvant (45 Gy) or adjuvant (54 Gy) radio(chemo)therapy in single fractions of 5 days a week 1.8 Gy for rectal carcinoma, using a photon energy of 15 MV. One group was positioned in a prone position without an immobilization device, the other group was positioned on our bellyboard. Treatment planning was calculated by using a 4- and a 3-field box technique. Differences in the dose of organs of risk were calculated. For 1 male patient, a gonadal shielding was developed and integrated. All patients examined with the bellyboard demonstrated an anterior and cranial dislocation of the small bowel. Using a 4-field box, the mean dose to the small bowel of patients treated on our bellyboard was 56.5% as compared to 63.1% when treated without the bellyboard. When a 3-field box was used, the mean dose to the small bowel was 52.4% when the bellyboard was used, as compared to a mean dose of 63.1% without the bellyboard. Regarding the dose volume effects to the bladder, the mean dose for patients treated with a 4-field box was about 14.5% higher as compared to patients treated with a 3-field box. The mean dose to the hip joints and skin also depended on the radiation technique. The patient who received gonadal shielding received a maximal total gonadal dose of about 75.0 cGy in single fractions of maximal 3.0 cGy (TL-dosimeters). Daily setup variations evaluated by a beam's-eye view were similar in both groups and ranged from 0.5 cm 1.0 cm. For daily use, our bellyboard appears to be an ideal compromise due to effectiveness, its easy handling, and reproductive positioning; moreover, it can also be used in combination with gonadal shielding.
Similar articles
-
Reduction of irradiated small bowel volume and accurate patient positioning by use of a bellyboard device in pelvic radiotherapy of gynecological cancer patients.Radiother Oncol. 2001 Apr;59(1):87-93. doi: 10.1016/s0167-8140(00)00279-6. Radiother Oncol. 2001. PMID: 11295211 Clinical Trial.
-
A phase II trial for the optimisation of treatment position in the radiation therapy of prostate cancer.Radiother Oncol. 2008 Jul;88(1):61-6. doi: 10.1016/j.radonc.2008.03.023. Epub 2008 Apr 29. Radiother Oncol. 2008. PMID: 18453021 Clinical Trial.
-
[Dosimetric analysis of radiotherapy with middle shielding blocks of different widths at the lower cervical supraclavicular field for stage N2-3 nasopharyngeal carcinoma].Ai Zheng. 2007 Oct;26(10):1127-32. Ai Zheng. 2007. PMID: 17927886 Chinese.
-
Preoperative radiation treatment for rectal cancer: comparison of target coverage and small bowel NTCP in conventional vs. 3D-conformal planning.Med Dosim. 2009 Spring;34(1):75-81. doi: 10.1016/j.meddos.2008.04.001. Epub 2008 Jun 9. Med Dosim. 2009. PMID: 19181259
-
A critical literature review on the use of bellyboard devices to control small bowel dose for pelvic radiotherapy.Rep Pract Oncol Radiother. 2020 Jul-Aug;25(4):598-605. doi: 10.1016/j.rpor.2020.04.019. Epub 2020 May 19. Rep Pract Oncol Radiother. 2020. PMID: 32518531 Free PMC article. Review.
Cited by
-
Dose-volume histogram predictors of chronic gastrointestinal complications after radical hysterectomy and postoperative intensity modulated radiotherapy for early-stage cervical cancer.BMC Cancer. 2014 Oct 29;14:789. doi: 10.1186/1471-2407-14-789. BMC Cancer. 2014. PMID: 25354964 Free PMC article.
-
Effect of Abdominal Circumference on the Irradiated Bowel Volume in Pelvic Radiotherapy for Rectal Cancer Patients: Implications for the Radiotherapy-Related Intestinal Toxicity.Front Oncol. 2022 Feb 23;12:843704. doi: 10.3389/fonc.2022.843704. eCollection 2022. Front Oncol. 2022. PMID: 35280741 Free PMC article.
MeSH terms
LinkOut - more resources
Full Text Sources
Miscellaneous